Japanese AntibaCterial drug maNagemEnt for cardiac Sarcoidosis Trial

Japanese AntibaCterial drug maNagemEnt for cardiac Sarcoidosis Trial - J-ACNES

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025936

Enrollment

Registered

2017-02-20

Start date

2017-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac sarcoidosis

Interventions

combination therapy group: Prednisolone

Predonisolone start from 30mg/day and continue same dose for one month. After one month, prednisolone decrease 25mg, 20mg, 15mg, 10mg every 2-4 weeks. Finally, maintenance dose of predonisolone is 7.5

Clarithromycin start from 400mg/day for 24weeks. Doxycycline start 100mg/day for 22 weeks after 2 months of clarithromycin therapy. Prednisolone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cardiac sarcoidosis patient who have positive finding of FDG-PET and/or Ga scintigram and indication of steroid therapy.

Exclusion criteria

Exclusion criteria: liver or kideny dysfunction, active infection, contraindication of drugs, corticosteroid therapy within 6 months for other disease, severe diabetes mellitus, and pregnancy

Design outcomes

Primary

Measure	Time frame
the change of SUV level from baseline in FDG-PET/CT examination (6 months after study enroll)	—

Secondary

Measure	Time frame
the frequency of steroid dose increasing (12 months after study enroll)	—

Countries

Japan

Contacts

Public ContactKengo Kusano

National cerebral and cardiovascular center department of cardiovascular medicine

kusanokengo@gmail.com0661701070

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026